AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda ...

After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multiyear deal to access Iambic Therapeutics' broad suite of& | ...

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...

Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

Researchers from The Ohio State University and the Indian Institute of Technology Madras have developed an artificial intelligence framework to rapidly generate drug-like molecules that are easier to ...

Drug discovery requires two separate steps: checking whether a drug can bind to a harmful molecule or its receptor, and ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

Promega has unveiled a live-cell target engagement platform that enables researchers to analyze understudied or intractable proteins in live cells. “You can now potentially study intracellular target ...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL), ahead of the American Association for Cancer Research® (AACR) Annual Meeting in Chicago, IL, has ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...